Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Gilead Sciences  /  Remdesivir

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Gilead Sciences OTC:GILD.Q, US3755581036

  • 65,680 24 mei 2024 22:00
  • -0,490 (-0,74%) Dagrange 65,210 - 66,430
  • 5.971.044 Gem. (3M) 6,9M

Remdesivir

136 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste | Omlaag ↓
  1. forum rang 5 Endless 13 juli 2020 11:00
    Third of S.Korea COVID-19 patients improve with remdesivir

    Jul. 13, 2020 4:50 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Yoel Minkoff, SA News Editor
    The Korea Centers for Disease Control and Prevention is reporting results from a first group of 27 patients given Gilead Sciences' (NASDAQ:GILD) remdesivir in different hospitals.

    One in three South Korean patients seriously ill with COVID-19 showed an improvement in their condition, though more research is needed to determine if the improvement was attributable to the drug or other factors like immunity and other therapies.

    Several other countries have added the drug to the list of treatment for the disease caused by the coronavirus.

    On Friday, Gilead said an analysis showed remdesivir helped reduce the risk of death in severely ill COVID-19 patients but cautioned that rigorous clinical trials were needed to confirm the benefit.
  4. forum rang 5 Endless 20 juli 2020 14:39
    Innovation Pharma's Brilacidin shows encouraging anti-SARS-CoV-2 action in preclinical testing

    Jul. 20, 2020 7:52 AM ET|About: Innovation Pharmaceuti... (IPIX)|By: Douglas W. House, SA News Editor
    Innovation Pharmaceuticals (OTCQB:IPIX) announces new data from ongoing lab testing of Brilacidin for COVID-19.

    In a human lung epithelial cell line, recently released data showed that Brilacidin reduced the coronavirus viral load by 95% and 97%, respectively, at two concentrations tested.

    The new results, based on the same assay method, demonstrated that a concentration 50% below the lower of the two previously tested concentrations of Brilacidin inhibited the coronavirus by ~90%.

    The company cites a Nature-published article that showed Gilead Sciences' (NASDAQ:GILD) remdesivir achieved 50% inhibition of SARS-CoV-2 in a time-of-addition experiment in animal cells.

    The data will be submitted for publication.

    A Phase 2 clinical trial should launch in Q4.
  6. forum rang 5 Endless 21 juli 2020 14:48
    quote:

    Ooievaar schreef op 14 juli 2020 09:21:

    Nou Endless als die 62% verbetering blijft staan dan moet dit iets met de koers doen. Gisteren was er ook een behoorlijke stijging maar misschien wel op dit nieuws, ik weet het niet.
    Ze zijn goed bezig (zie tweet) niet alles draait om remdesivir
  10. forum rang 5 Endless 2 augustus 2020 22:48
    Gilead Sciences (GILD:UN)
    69.51 2.82 (3.89%)
    As of: 08/02/20 4:43:57 pm
    (delayed at least 15 minutes)
    10. May
    24. May
    8. Jun
    20. Jun
    6. Jul
    20. Jul
    2. Aug
    65
    70
    75
    80
    85
    90
    Chart Type - 3month
    See Full Stock Page »
    Health Canada has authorized the use of Gilead Sciences Canada Inc.’s remdesivir drug to treat people with severe COVID-19 symptoms on Tuesday, making this the first drug the regulator has approved to treat the virus.
    The use of remdesivir is authorized only under certain conditions, Health Canada said. It has been approved for use in adults and adolescents aged 12 years or older.
    Health Canada’s other conditions include that the manufacturer ensures the continued safety, efficacy, and quality of the drug. The regulator said it will closely monitor how remdesivir is prescribed to patients and will take action if any concerns arise.
    "We appreciate Health Canada's expedited review of Veklury (the brand name for remdesivir) in recognition of the urgent need to treat COVID-19 patients in Canada," Gilead Sciences Canada General Manager Melissa Koomey said in a release Tuesday. "We are thankful for their collaboration and leadership, as we together work to respond to this public health emergency."
    The drug has been given emergency or conditional authorization in some other countries including the United States, Japan, Europe and Australia.
    In Canada, some COVID-19 patients have already been treated with remdesivir under the regulator's ?Special Access Program.
  16. forum rang 5 Endless 10 augustus 2020 19:34
    Gilead Sciences files U.S. application for remdesivir for COVID-19

    Aug. 10, 2020 12:13 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (GILD -1.7%) has completed its rolling marketing application to the FDA seeking full approval of Veklury (remdesivir) for the treatment of severely ill hospitalized COVID-19 patients. It initiated the process on April 8.

    The FDA approved the emergency use of the antiviral for these patients on May 1. It remains the only medicine to receive the nod in the U.S. to date. It is also available in Europe, Japan, India, Australia and Canada.
136 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Aantrekkelijk gewaardeerd Gilead is niet issue-vrij

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Gilead Sciences Nieuws

  1. 03 aug Gilead verlaagt outlook
  2. apr '23 Gilead schiet tekort
  3. feb '23 Hogere resultaten Gilead
  4. aug '22 Hogere omzet Gilead
  5. apr '22 Gilead verlaagt outlook
  6. feb '22 Schikking drukt winst Gilead
  7. okt '21 Gilead verhoogt outlook
  8. apr '21 Gilead profiteert minder van remdesivir
  9. apr '21 Biden wil medicijnkosten flink verlagen - media 14
  10. apr '21 Goedkeuringsaanvraag voor filgotinib ingediend in Japan voor behandeling darmziekte

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!